查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2010052

成癮藥物市場：2026-2032年全球市場預測（按產品類型、劑型、給藥途徑、藥物類別、分銷管道和最終用戶分類）

Addiction Disorders Drugs Market by Product Type, Dosage Form, Administration Route, Drug Class, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，成癮藥物市場價值將達到 288.9 億美元，到 2026 年將成長到 306.7 億美元，到 2032 年將達到 453.4 億美元，複合年成長率為 6.65%。

主要市場統計數據
基準年 2025 288.9億美元
預計年份：2026年 306.7億美元
預測年份 2032 453.4億美元
複合年成長率 (%) 6.65%

簡要概述當前影響成癮治療和策略決策的臨床、監管和商業性趨勢。

成癮是一個持續且不斷演變的公共衛生挑戰，涉及臨床實踐、法律規範和商業策略的交匯點。本執行摘要整合了治療方法、給藥技術和護理服務模式的最新進展，旨在幫助相關人員確定投資重點並應對營運風險。本文重點關注藥物創新、與學名藥的競爭以及不斷演變的患者就醫途徑之間的相互作用，從實用觀點出發，為臨床、監管和商業部門的決策提供支持。

概述了正在重塑成癮治療中治療方法的採用和競爭動態的關鍵技術、監管和護理模式變革。

成癮藥物治療領域正經歷著一場變革，其驅動力包括患者期望的提高、藥物傳輸技術的進步以及醫療服務管道的變革。新的製劑技術使得藥物作用時間更長、依從性更高成為可能，迫使保險公司和醫療服務提供者重新評估治療流程。同時，數位療法和遠端醫療的融合，正以行為科學為基礎，為藥物治療提供補充，並將治療範圍擴展到傳統診所之外。

本研究分析了累積關稅措施如何重塑整個成癮治療供應鏈的韌性、籌資策略和製造在地化。

關稅措施的累積影響為成癮治療領域的採購、生產選擇和定價策略帶來了新的複雜性。關稅相關的成本壓力促使企業重新評估其供應商網路，盡可能優先考慮在地採購，重新談判長期供應合約以穩定投入成本，並降低對政策突變的脆弱性。這些調整對依賴全球活性成分採購的學名藥生產商以及維持複雜多層供應鏈的品牌藥開發商都具有重大意義。

為了實現策略清晰，我們進行了多層次的細分分析，將產品形式、給藥途徑和治療領域與分銷管道和最終用戶的實際情況聯繫起來。

一套精細的市場區隔架構清楚展現了臨床需求、生產複雜性和商業性差異化之間的交集。我們首先檢視產品類型，調查品牌藥和學名藥的供應情況，每種產品在定價、監管環境和商業化方面都有其獨特的考量。在劑型方面，我們研究了膠囊、薄膜、注射、貼片和片劑等各種劑型的市場情況，每種劑型都面臨不同的配方挑戰、患者遵從性和分銷要求。最後，我們考慮給藥途徑，包括注射、口服、舌下和經皮，每種途徑都會影響起效速度、監測需求以及對不同患者群體的適用性。

區域間在監管多樣性、醫療保健服務模式和製造業實力方面的觀點，造成了醫療服務取得和普及趨勢的差異。

區域趨勢影響著醫療服務的可近性、監管路徑和商業性模式。首先，在美洲，醫療保健體系涵蓋了以公共保險主導的模式以及公私混合模式。政策辯論和報銷機制對該地區處方藥的上市和推廣時間表有顯著影響。臨床醫生網路、專科治療中心和減害措施是影響治療推廣和持續性的關鍵相關人員。此外，美洲在整合式醫療模式方面不斷創新，將藥物治療與行為療法和數位化支持相結合，從而改變了治療方法的處方和監測方式。

深入了解創新者、非專利生產商、契約製造生產商、經銷商和數位健康合作夥伴在塑造競爭定位和合作中的作用。

成癮治療領域的競爭動態是由許多創新公司、專業製藥公司、非專利生產商、合約研發生產機構 (CDMO) 以及分銷合作夥伴共同塑造的。創新公司專注於透過新型配方、緩釋平台和拓展適應症來提升治療效用，從而實現差異化；而非專利生產商則優先考慮成本競爭力、供應可靠性和監管靈活性，以獲得進入大眾市場管道的機會。契約製造生產商和 CDMO 在擴大產能、快速擴大新劑型規模以及分散品牌藥和非專利組合的風險方面發揮著至關重要的作用。

透過加強供應韌性、創新給藥形式和整合照護模式，採取實際有效的策略步驟，加速推廣應用並改善治療效果。

該領域的領導者應採取一系列切實有效且影響深遠的措施，以增強韌性、加速部署並改善患者治療效果。首先，應優先投資於製劑和給藥途徑的創新，以解決用藥依從性和監測方面的挑戰，並使產品開發與患者的實際需求和支付方的證據要求保持一致。其次，應透過雙重採購、區域製造能力和透明的供應商關係來增強供應鏈韌性，同時控制成本並降低地緣政治和關稅相關風險。

採用高度透明的混合方法研究方法，結合嚴謹的二手資料分析、針對性的一手訪談和情境評估，以獲得可靠的見解。

本研究途徑結合了對二手證據的系統性回顧和有針對性的一手調查，以期獲得廣度和深度兼具的洞見。二手分析包括同行評審文獻、臨床指南綜述、監管文件以及現有的匿名處方和使用資料集。這些資訊來源為分析提供了潛在的臨床和監管背景、歷史治療模式以及已發表的安全性和有效性數據。在二手分析階段，我們優先考慮透明度、可重複性和資訊來源的仔細檢驗，以避免過度依賴單一資訊來源。

在不斷變化的成癮治療領域中，將臨床創新、供應彈性和對綜合護理的投資轉化為策略優勢的關鍵點。

總而言之，目前成癮藥物治療的現況呈現出多種因素交互作用的複雜局面，既存在風險也蘊藏機會。給藥方法和製劑的創新，以及不斷擴展的綜合護理模式，正促使人們重新審視藥物的採納，不再僅僅關注傳統的療效指標，而是更加關注患者體驗、用藥依從性和系統整合。同時，地緣政治和政策趨勢也促使人們重新評估供應鏈設計和籌資策略，進一步凸顯了韌性和彈性的重要性。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：成癮治療市場：依產品類型分類

  • 品牌商品
  • 非專利的

第9章：以劑型分類的成癮治療市場

  • 膠囊
  • 電影
  • 注射液
  • 修補
  • 藥片

第10章：按給藥途徑分類的成癮治療市場

  • 注射藥物
  • 口服
  • 舌下
  • 經皮

第11章：成癮治療市場：依藥物類別分類

  • 酒精
    • Acamprosate
    • Disulfiram
    • 納曲酮
  • 尼古丁
    • Varenicline
  • 鴉片類藥物
    • Buprenornhine
    • 梅塔頓
    • 納曲酮

第12章：成癮治療市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第13章：成癮治療市場：依最終使用者分類

  • 診所
  • 居家照護設施
  • 醫院

第14章：成癮治療市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章：成癮治療市場：依群體分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章：成癮治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國成癮治療市場

第18章：中國成癮治療市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Accord Healthcare Limited
  • Alkermes plc
  • Aurobindo Pharma Limited
  • Bausch Health Companies Inc
  • BioDelivery Sciences International Inc
  • Camurus AB
  • Cipla Limited
  • GlaxoSmithKline PLC
  • Hikma Pharmaceuticals PLC
  • Indivior PLC
  • Insys Therapeutics Inc
  • Johnson & Johnson
  • Mallinckrodt Pharmaceuticals PLC
  • Orexo AB
  • Pfizer Inc
  • Purdue Pharma LP
  • Reckitt Benckiser Pharmaceuticals Inc
  • Teva Pharmaceutical Industries Ltd
  • Titan Pharmaceuticals Inc
  • Viatris Inc
Product Code: MRR-434CCDA05183

The Addiction Disorders Drugs Market was valued at USD 28.89 billion in 2025 and is projected to grow to USD 30.67 billion in 2026, with a CAGR of 6.65%, reaching USD 45.34 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 28.89 billion
Estimated Year [2026] USD 30.67 billion
Forecast Year [2032] USD 45.34 billion
CAGR (%) 6.65%

A concise orientation to the current clinical, regulatory, and commercial dynamics shaping addiction disorder therapies and strategic decision making

Addiction disorders present a persistent and evolving public health challenge that intersects clinical practice, regulatory oversight, and commercial strategy. This executive summary synthesizes the latest developments across therapeutic modalities, delivery technologies, and care delivery models to help stakeholders prioritize investments and respond to operational risks. It emphasizes the interplay between pharmacologic innovation, generic competition, and shifting patient access pathways while framing the discussion in a pragmatic way that supports decision making across clinical, regulatory, and commercial functions.

Patients, payers, providers, and manufacturers are adapting to a landscape where treatment expectations are changing and where integrated care models increasingly determine outcomes. As a result, therapeutic selection is not only influenced by efficacy and safety but also by formulation, route of administration, and distribution flexibility that together shape adherence and continuity of care. The introduction of novel formulations and the repositioning of established therapies for extended indications have intensified competition and created new opportunities for differentiation through patient-centric delivery systems.

This summary highlights transformative shifts and regulatory pressures, examines how tariff dynamics are reshaping procurement and supply chain strategies, and articulates segmentation and regional perspectives critical for strategic planning. The intent is to equip decision-makers with a clear, evidence-based narrative that supports targeted investment and operational adjustments in the near term and over a multi-year horizon.

An overview of the major technological, regulatory, and care model shifts reshaping therapeutic adoption and competitive dynamics in addiction treatment

The landscape for addiction disorder therapeutics is undergoing transformative shifts driven by patient expectations, technological advances in drug delivery, and changes in care delivery pathways. New formulation technologies are enabling longer-acting and more adherent-compatible options, which in turn are prompting payers and providers to reassess treatment algorithms. Concurrently, digital therapeutics and telehealth integration are supplementing pharmacologic approaches with behaviorally informed support, expanding the scope of treatment beyond traditional clinic walls.

Consolidation across specialty pharmacies, distributors, and contract manufacturers is altering bargaining power and creating opportunities for vertically integrated models that enhance supply resilience and reduce time to patient. Regulatory flexibility around expanded labeling and risk evaluation plans is enabling faster uptake of repurposed agents, while ongoing vigilance on safety profiles continues to shape prescribing behavior. Moreover, the maturation of real-world evidence generation is providing payers and clinicians with richer data on comparative effectiveness, adherence patterns, and long-term outcomes, thereby influencing coverage and formulary decisions.

Taken together, these shifts underscore a move toward holistic care models that combine pharmaceutical innovation with delivery systems and digital supports. For stakeholders, the priority is to align product development, commercial strategy, and evidence generation to these broader care trends so that therapies are optimized for both clinical impact and real-world adoption.

Analyzing how cumulative tariff measures have reshaped supply chain resilience, procurement strategies, and manufacturing localization across addiction therapy supply chains

The cumulative effect of tariff actions has introduced a new layer of complexity to procurement, manufacturing choices, and pricing strategies for addiction disorder therapies. Tariff-related cost pressures have incentivized firms to reassess supplier networks, prioritize local sourcing where feasible, and renegotiate long-term supply agreements to stabilize input costs and reduce vulnerability to sudden policy shifts. These adjustments have implications for generic manufacturers that rely on global active pharmaceutical ingredient sourcing and for branded developers that maintain complex, multi-tiered supply chains.

In response to tariff pressures, pharmaceutical firms are accelerating strategic initiatives such as nearshoring of critical manufacturing steps, investment in dual sourcing, and increased inventory buffers to preserve continuity of supply. These mitigation tactics, while practical, can increase operational complexity and working capital requirements. At the same time, health systems and payers are reviewing procurement frameworks to favor suppliers with demonstrated supply chain resilience, preferring predictable availability over marginal price advantages when disruptions could compromise patient care.

Regulatory agencies and trade policymakers are also part of the equation, as changes in import duties can prompt adaptive policy interventions and bilateral negotiations that alter the competitive environment. Ultimately, the combined effect of tariffs and corresponding industry responses is a heightened emphasis on supply chain transparency, risk management, and collaboration between manufacturers, distributors, and health systems to ensure uninterrupted access to essential addiction disorder therapies.

A layered segmentation analysis linking product formats, administration routes, and therapeutic classes to distribution channels and end-user realities for strategic clarity

A nuanced segmentation framework clarifies where clinical demand, manufacturing complexity, and commercial differentiation converge, starting with product type where the landscape is examined across branded and generic offerings, each bringing distinct pricing, regulatory, and commercialization considerations. Moving to dosage form, the market is studied across capsule, film, injectable solution, patch, and tablet formats, which carry different formulation challenges, patient adherence profiles, and distribution requirements. Administration route is considered across injectable, oral, sublingual, and transdermal pathways, with each route influencing onset of action, monitoring needs, and suitability for diverse patient populations.

Drug class segmentation is particularly instructive for clinical and portfolio strategy. The alcohol disorder category is examined across acamprosate, disulfiram, and naltrexone, with each of these agents further analyzed in terms of branded and generic availability and their implications for treatment positioning. Nicotine dependence therapies are assessed across bupropion, nicotine replacement therapy, and varenicline; bupropion and varenicline are evaluated for branded and generic dynamics while nicotine replacement therapy is explored across gum, inhaler, lozenge, and patch forms that differ in pharmacokinetics and patient preference. The opioid disorder category includes buprenorphine, methadone, and naltrexone, with attention to branded and generic variations that affect access, prescriber behavior, and dispensing controls.

Distribution channel segmentation examines hospital pharmacy, online pharmacy, and retail pharmacy pathways, recognizing that each channel has different regulatory compliance, reimbursement mechanisms, and opportunities for patient engagement. Finally, end user segmentation covers clinics, homecare settings, and hospitals, highlighting how the locus of care influences adherence support, monitoring intensity, and adoption of novel delivery systems. Together, this layered segmentation provides a granular lens through which product development, commercialization, and health system strategies can be aligned to clinical and operational realities.

Regional perspectives on regulatory diversity, care delivery models, and manufacturing strengths that drive differentiated access and adoption dynamics

Regional dynamics shape access, regulatory pathways, and commercial approaches, beginning with the Americas where health systems vary from public payer-driven models to mixed public-private arrangements. In this region, policy debates and reimbursement frameworks strongly influence formulary placement and adoption timelines. Clinician networks, specialty treatment centers, and harm-reduction initiatives are critical stakeholders that affect uptake and continuity of care. Additionally, the Americas continue to witness innovation in integrated care models that combine pharmacotherapy with behavioral and digital supports, which alters how therapies are prescribed and monitored.

The Europe, Middle East & Africa region presents a diverse regulatory mosaic with differing approval timelines, pricing controls, and reimbursement mechanisms. In many jurisdictions, centralized procurement and stringent cost-effectiveness evaluations determine access, while subregional variations in care infrastructure influence distribution channel strategy. The region also sees growing emphasis on community-based programs and public health interventions that prioritize broad access to evidence-based therapies, which shapes demand for formulations that support adherence and simplified delivery.

Asia-Pacific is characterized by rapid adoption of novel delivery technologies, expanding private healthcare sectors, and strong manufacturing capabilities that position the region as both a consumer and producer of addiction disorder therapeutics. Regulatory harmonization efforts and investments in local manufacturing are creating opportunities for faster market entry, while telehealth expansion is enabling distributed models of care that reach underserved populations. Across regions, stakeholders must tailor commercialization, evidence generation, and supply chain strategies to local payer dynamics and care delivery configurations.

Insights into the roles of innovators, generics, contract manufacturers, distributors, and digital health partners shaping competitive positioning and collaboration

Competitive dynamics in the addiction therapies arena are shaped by a mix of originator companies, specialty manufacturers, generic producers, contract development and manufacturing organizations, and distribution partners. Innovator firms are focused on differentiation through novel formulations, extended-release platforms, and indications that expand therapeutic utility, while generic manufacturers emphasize cost competitiveness, supply reliability, and regulatory agility to capture volume-driven channels. Contract manufacturers and CDMOs play a pivotal role in enabling capacity expansion, rapid scale-up of new dosage forms, and risk diversification for both branded and generic portfolios.

Distribution and specialty pharmacy players are increasingly influential in shaping patient access, particularly for therapies requiring close monitoring or restricted dispensing. These intermediaries are integrating services such as adherence support, prior-authorization management, and home delivery, which affect patient continuity and payer perceptions. Meanwhile, digital health companies and telemedicine providers are emerging as complementary stakeholders that drive engagement and long-term management, especially when pharmacotherapy is combined with behavioral interventions.

Across these categories, alliances and strategic partnerships are common as organizations seek to combine clinical expertise, supply chain resilience, and channel reach. The most successful companies are those that integrate evidence generation with market access planning, invest in patient support infrastructure, and demonstrate operational agility to respond to regulatory and policy shifts. For decision-makers, understanding these competitive roles is essential to identifying potential collaborators, acquisition targets, and differentiation opportunities within portfolios.

Practical high-impact strategic steps for strengthening supply resilience, innovating delivery formats, and integrating care models to drive adoption and outcomes

Leaders in the field should pursue a set of pragmatic, high-impact actions to strengthen resilience, accelerate adoption, and improve patient outcomes. First, prioritize investments in formulation and route of administration innovations that address adherence and monitoring challenges, aligning product development with real-world patient needs and payer evidence requirements. Second, strengthen supply chain resilience through dual sourcing, regional manufacturing capacity, and transparent supplier relationships to mitigate geopolitical and tariff-related risks while maintaining cost discipline.

Third, build integrated value propositions that combine pharmacologic therapy with behavioral, digital, and telehealth supports to enhance outcomes and create payer-relevant differentiation. Fourth, engage early and proactively with payers and regulatory bodies to ensure that clinical development and evidence generation plans meet real-world decision criteria, smoothing pathways to coverage and uptake. Fifth, establish distribution strategies that reflect channel-specific dynamics, including partnerships with specialty and online pharmacies where adherence support and patient management services can be delivered effectively.

Finally, adopt an outcomes-focused commercial model that measures real-world effectiveness, patient retention, and health economic impact to guide portfolio prioritization and pricing discussions. By implementing these actions, organizations can better navigate policy uncertainty, enhance patient access, and create durable competitive advantages in the evolving treatment landscape.

A transparent mixed-methods research pathway combining rigorous secondary analysis with targeted primary interviews and scenario assessment for robust insights

The research approach combined systematic secondary evidence review with targeted primary engagement to ensure both breadth and depth of insight. Secondary analysis included peer-reviewed literature, clinical guideline reviews, regulatory documentation, and anonymized prescription and utilization datasets where accessible. These sources established the clinical and regulatory context, historical treatment patterns, and published safety and efficacy profiles that anchor the analysis. The secondary phase prioritized transparency, reproducibility, and careful source triangulation to avoid undue reliance on any single information stream.

Primary research complemented secondary findings through structured interviews with clinicians, specialty pharmacists, payer representatives, and manufacturing and distribution executives. These engagements provided contemporary perspectives on adoption barriers, supply chain practices, and formulary decision drivers. Interview protocols were designed to elicit practical insights on adherence challenges, real-world outcomes, and operational considerations for different dosage forms and administration routes. Responses were anonymized and synthesized to identify convergent themes and dissenting viewpoints.

Analytical methods included qualitative synthesis, comparative assessment of formulation and delivery trade-offs, and scenario analysis focused on supply chain and policy contingencies. Throughout, the methodology emphasized balanced interpretation, rigorous cross-validation of evidence, and clear documentation of assumptions and limitations so that users can assess applicability to their specific strategic questions.

Key takeaways that tie clinical innovation, supply resilience, and integrated care investments to strategic advantage in the evolving addiction treatment environment

In summary, the addiction disorder therapeutics landscape is characterized by converging forces that create both risk and opportunity. Innovations in delivery and formulation, combined with expanding models of integrated care, are shifting the determinants of adoption beyond classical efficacy metrics to include patient experience, adherence, and system integration. At the same time, geopolitical and policy developments are prompting a reappraisal of supply chain design and procurement strategies, reinforcing the importance of resilience and agility.

Strategically, organizations that align product development with payer and provider evidence needs, invest in differentiated delivery mechanisms, and build partnerships across distribution and digital health channels will be best positioned to capture clinical and commercial value. Operationally, strengthening supplier relationships, diversifying manufacturing footprints, and enhancing transparency will mitigate exposure to tariff and policy volatility. Finally, prioritizing real-world evidence generation and outcomes measurement will support coverage decisions and demonstrate value to stakeholders across the continuum of care.

Taken together, these conclusions suggest a pathway for action that balances near-term operational safeguards with medium-term investments in innovation and integrated care capabilities, thereby improving the prospects for sustainable impact in patient outcomes and organizational performance.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Addiction Disorders Drugs Market, by Product Type

  • 8.1. Branded
  • 8.2. Generic

9. Addiction Disorders Drugs Market, by Dosage Form

  • 9.1. Capsule
  • 9.2. Film
  • 9.3. Injectable Solution
  • 9.4. Patch
  • 9.5. Tablet

10. Addiction Disorders Drugs Market, by Administration Route

  • 10.1. Injectable
  • 10.2. Oral
  • 10.3. Sublingual
  • 10.4. Transdermal

11. Addiction Disorders Drugs Market, by Drug Class

  • 11.1. Alcohol
    • 11.1.1. Acamprosate
    • 11.1.2. Disulfiram
    • 11.1.3. Naltrexone
  • 11.2. Nicotine
    • 11.2.1. Varenicline
  • 11.3. Opioid
    • 11.3.1. Buprenorphine
    • 11.3.2. Methadone
    • 11.3.3. Naltrexone

12. Addiction Disorders Drugs Market, by Distribution Channel

  • 12.1. Hospital Pharmacy
  • 12.2. Online Pharmacy
  • 12.3. Retail Pharmacy

13. Addiction Disorders Drugs Market, by End User

  • 13.1. Clinics
  • 13.2. Homecare Settings
  • 13.3. Hospitals

14. Addiction Disorders Drugs Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Addiction Disorders Drugs Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Addiction Disorders Drugs Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Addiction Disorders Drugs Market

18. China Addiction Disorders Drugs Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Accord Healthcare Limited
  • 19.6. Alkermes plc
  • 19.7. Aurobindo Pharma Limited
  • 19.8. Bausch Health Companies Inc
  • 19.9. BioDelivery Sciences International Inc
  • 19.10. Camurus AB
  • 19.11. Cipla Limited
  • 19.12. GlaxoSmithKline PLC
  • 19.13. Hikma Pharmaceuticals PLC
  • 19.14. Indivior PLC
  • 19.15. Insys Therapeutics Inc
  • 19.16. Johnson & Johnson
  • 19.17. Mallinckrodt Pharmaceuticals PLC
  • 19.18. Orexo AB
  • 19.19. Pfizer Inc
  • 19.20. Purdue Pharma L.P.
  • 19.21. Reckitt Benckiser Pharmaceuticals Inc
  • 19.22. Teva Pharmaceutical Industries Ltd
  • 19.23. Titan Pharmaceuticals Inc
  • 19.24. Viatris Inc

LIST OF FIGURES

  • FIGURE 1. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ADDICTION DISORDERS DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ADDICTION DISORDERS DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES ADDICTION DISORDERS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA ADDICTION DISORDERS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY BRANDED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY BRANDED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY BRANDED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY GENERIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY GENERIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY GENERIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY CAPSULE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY CAPSULE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY CAPSULE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY FILM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY FILM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY FILM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY INJECTABLE SOLUTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY INJECTABLE SOLUTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY INJECTABLE SOLUTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY PATCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY PATCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY PATCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY TABLET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY TABLET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY SUBLINGUAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY SUBLINGUAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY SUBLINGUAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY TRANSDERMAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY TRANSDERMAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY ALCOHOL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY ALCOHOL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY ALCOHOL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY ALCOHOL, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY ACAMPROSATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY ACAMPROSATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY ACAMPROSATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY DISULFIRAM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY DISULFIRAM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY DISULFIRAM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY NALTREXONE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY NALTREXONE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY NALTREXONE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY NICOTINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY NICOTINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY NICOTINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY NICOTINE, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY VARENICLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY VARENICLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY VARENICLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY OPIOID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY OPIOID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY OPIOID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY OPIOID, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY BUPRENORPHINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY BUPRENORPHINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY BUPRENORPHINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY METHADONE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY METHADONE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY METHADONE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY NALTREXONE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY NALTREXONE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY NALTREXONE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS ADDICTION DISORDERS DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS ADDICTION DISORDERS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS ADDICTION DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 96. AMERICAS ADDICTION DISORDERS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 97. AMERICAS ADDICTION DISORDERS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 98. AMERICAS ADDICTION DISORDERS DRUGS MARKET SIZE, BY ALCOHOL, 2018-2032 (USD MILLION)
  • TABLE 99. AMERICAS ADDICTION DISORDERS DRUGS MARKET SIZE, BY NICOTINE, 2018-2032 (USD MILLION)
  • TABLE 100. AMERICAS ADDICTION DISORDERS DRUGS MARKET SIZE, BY OPIOID, 2018-2032 (USD MILLION)
  • TABLE 101. AMERICAS ADDICTION DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS ADDICTION DISORDERS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY ALCOHOL, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY NICOTINE, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY OPIOID, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 117. LATIN AMERICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 118. LATIN AMERICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY ALCOHOL, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY NICOTINE, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY OPIOID, 2018-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY ALCOHOL, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY NICOTINE, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY OPIOID, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE ADDICTION DISORDERS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE ADDICTION DISORDERS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE ADDICTION DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE ADDICTION DISORDERS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE ADDICTION DISORDERS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE ADDICTION DISORDERS DRUGS MARKET SIZE, BY ALCOHOL, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE ADDICTION DISORDERS DRUGS MARKET SIZE, BY NICOTINE, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE ADDICTION DISORDERS DRUGS MARKET SIZE, BY OPIOID, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE ADDICTION DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE ADDICTION DISORDERS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST ADDICTION DISORDERS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. MIDDLE EAST ADDICTION DISORDERS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. MIDDLE EAST ADDICTION DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST ADDICTION DISORDERS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 147. MIDDLE EAST ADDICTION DISORDERS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 148. MIDDLE EAST ADDICTION DISORDERS DRUGS MARKET SIZE, BY ALCOHOL, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST ADDICTION DISORDERS DRUGS MARKET SIZE, BY NICOTINE, 2018-2032 (USD MILLION)
  • TABLE 150. MIDDLE EAST ADDICTION DISORDERS DRUGS MARKET SIZE, BY OPIOID, 2018-2032 (USD MILLION)
  • TABLE 151. MIDDLE EAST ADDICTION DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST ADDICTION DISORDERS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 153. AFRICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. AFRICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. AFRICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 156. AFRICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 157. AFRICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 158. AFRICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY ALCOHOL, 2018-2032 (USD MILLION)
  • TABLE 159. AFRICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY NICOTINE, 2018-2032 (USD MILLION)
  • TABLE 160. AFRICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY OPIOID, 2018-2032 (USD MILLION)
  • TABLE 161. AFRICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 162. AFRICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC ADDICTION DISORDERS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 164. ASIA-PACIFIC ADDICTION DISORDERS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC ADDICTION DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC ADDICTION DISORDERS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 167. ASIA-PACIFIC ADDICTION DISORDERS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 168. ASIA-PACIFIC ADDICTION DISORDERS DRUGS MARKET SIZE, BY ALCOHOL, 2018-2032 (USD MILLION)
  • TABLE 169. ASIA-PACIFIC ADDICTION DISORDERS DRUGS MARKET SIZE, BY NICOTINE, 2018-2032 (USD MILLION)
  • TABLE 170. ASIA-PACIFIC ADDICTION DISORDERS DRUGS MARKET SIZE, BY OPIOID, 2018-2032 (USD MILLION)
  • TABLE 171. ASIA-PACIFIC ADDICTION DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 172. ASIA-PACIFIC ADDICTION DISORDERS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN ADDICTION DISORDERS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. ASEAN ADDICTION DISORDERS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. ASEAN ADDICTION DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 177. ASEAN ADDICTION DISORDERS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 178. ASEAN ADDICTION DISORDERS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 179. ASEAN ADDICTION DISORDERS DRUGS MARKET SIZE, BY ALCOHOL, 2018-2032 (USD MILLION)
  • TABLE 180. ASEAN ADDICTION DISORDERS DRUGS MARKET SIZE, BY NICOTINE, 2018-2032 (USD MILLION)
  • TABLE 181. ASEAN ADDICTION DISORDERS DRUGS MARKET SIZE, BY OPIOID, 2018-2032 (USD MILLION)
  • TABLE 182. ASEAN ADDICTION DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 183. ASEAN ADDICTION DISORDERS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 184. GCC ADDICTION DISORDERS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 185. GCC ADDICTION DISORDERS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. GCC ADDICTION DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 187. GCC ADDICTION DISORDERS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 188. GCC ADDICTION DISORDERS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 189. GCC ADDICTION DISORDERS DRUGS MARKET SIZE, BY ALCOHOL, 2018-2032 (USD MILLION)
  • TABLE 190. GCC ADDICTION DISORDERS DRUGS MARKET SIZE, BY NICOTINE, 2018-2032 (USD MILLION)
  • TABLE 191. GCC ADDICTION DISORDERS DRUGS MARKET SIZE, BY OPIOID, 2018-2032 (USD MILLION)
  • TABLE 192. GCC ADDICTION DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 193. GCC ADDICTION DISORDERS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPEAN UNION ADDICTION DISORDERS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPEAN UNION ADDICTION DISORDERS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPEAN UNION ADDICTION DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPEAN UNION ADDICTION DISORDERS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPEAN UNION ADDICTION DISORDERS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPEAN UNION ADDICTION DISORDERS DRUGS MARKET SIZE, BY ALCOHOL, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPEAN UNION ADDICTION DISORDERS DRUGS MARKET SIZE, BY NICOTINE, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPEAN UNION ADDICTION DISORDERS DRUGS MARKET SIZE, BY OPIOID, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPEAN UNION ADDICTION DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPEAN UNION ADDICTION DISORDERS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 204. BRICS ADDICTION DISORDERS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 205. BRICS ADDICTION DISORDERS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. BRICS ADDICTION DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 207. BRICS ADDICTION DISORDERS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 208. BRICS ADDICTION DISORDERS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 209. BRICS ADDICTION DISORDERS DRUGS MARKET SIZE, BY ALCOHOL, 2018-2032 (USD MILLION)
  • TABLE 210. BRICS ADDICTION DISORDERS DRUGS MARKET SIZE, BY NICOTINE, 2018-2032 (USD MILLION)
  • TABLE 211. BRICS ADDICTION DISORDERS DRUGS MARKET SIZE, BY OPIOID, 2018-2032 (USD MILLION)
  • TABLE 212. BRICS ADDICTION DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 213. BRICS ADDICTION DISORDERS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 214. G7 ADDICTION DISORDERS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 215. G7 ADDICTION DISORDERS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 216. G7 ADDICTION DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 217. G7 ADDICTION DISORDERS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 218. G7 ADDICTION DISORDERS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 219. G7 ADDICTION DISORDERS DRUGS MARKET SIZE, BY ALCOHOL, 2018-2032 (USD MILLION)
  • TABLE 220. G7 ADDICTION DISORDERS DRUGS MARKET SIZE, BY NICOTINE, 2018-2032 (USD MILLION)
  • TABLE 221. G7 ADDICTION DISORDERS DRUGS MARKET SIZE, BY OPIOID, 2018-2032 (USD MILLION)
  • TABLE 222. G7 ADDICTION DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 223. G7 ADDICTION DISORDERS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 224. NATO ADDICTION DISORDERS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 225. NATO ADDICTION DISORDERS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 226. NATO ADDICTION DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 227. NATO ADDICTION DISORDERS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 228. NATO ADDICTION DISORDERS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 229. NATO ADDICTION DISORDERS DRUGS MARKET SIZE, BY ALCOHOL, 2018-2032 (USD MILLION)
  • TABLE 230. NATO ADDICTION DISORDERS DRUGS MARKET SIZE, BY NICOTINE, 2018-2032 (USD MILLION)
  • TABLE 231. NATO ADDICTION DISORDERS DRUGS MARKET SIZE, BY OPIOID, 2018-2032 (USD MILLION)
  • TABLE 232. NATO ADDICTION DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 233. NATO ADDICTION DISORDERS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 234. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 235. UNITED STATES ADDICTION DISORDERS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 236. UNITED STATES ADDICTION DISORDERS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 237. UNITED STATES ADDICTION DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 238. UNITED STATES ADDICTION DISORDERS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 239. UNITED STATES ADDICTION DISORDERS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 240. UNITED STATES ADDICTION DISORDERS DRUGS MARKET SIZE, BY ALCOHOL, 2018-2032 (USD MILLION)
  • TABLE 241. UNITED STATES ADDICTION DISORDERS DRUGS MARKET SIZE, BY NICOTINE, 2018-2032 (USD MILLION)
  • TABLE 242. UNITED STATES ADDICTION DISORDERS DRUGS MARKET SIZE, BY OPIOID, 2018-2032 (USD MILLION)
  • TABLE 243. UNITED STATES ADDICTION DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 244. UNITED STATES ADDICTION DISORDERS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 245. CHINA ADDICTION DISORDERS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 246. CHINA ADDICTION DISORDERS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 247. CHINA ADDICTION DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 248. CHINA ADDICTION DISORDERS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 249. CHINA ADDICTION DISORDERS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 250. CHINA ADDICTION DISORDERS DRUGS MARKET SIZE, BY ALCOHOL, 2018-2032 (USD MILLION)
  • TABLE 251. CHINA ADDICTION DISORDERS DRUGS MARKET SIZE, BY NICOTINE, 2018-2032 (USD MILLION)
  • TABLE 252. CHINA ADDICTION DISORDERS DRUGS MARKET SIZE, BY OPIOID, 2018-2032 (USD MILLION)
  • TABLE 253. CHINA ADDICTION DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 254. CHINA ADDICTION DISORDERS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)